Helicobacter pylori resistance to metronidazole, clarithromycin and amoxicillin in Colombian patients;Resistencia de Helicobacter pylori a metronidazol, claritromicina y amoxicilina en pacientes Colombianos

Revista Colombiana de Gastroenterologia

Volumn 25, Issue 1, 2010, Pages 31-38

  Trespalacios, Alba Alicia ^a   Regino, William Otero ^b,c   Reyes, Marcela Mercado ^a  

^a PONTIFICIA UNIVERSIDAD JAVERIANA   (Colombia)

^b UNIVERSIDAD NACIONAL DE COLOMBIA   (Colombia)

^c Unidad de Gastroenterología Clínica Fundadores   (Colombia)

Author keywords

Amoxicillin; Clarithromycin; Genotypes; Helicobacter pylori; Metronidazole

Indexed keywords

EID: 77956976677     PISSN: 01209957     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. Malaty HM. Epidemiology of Helicobacter pylori. Best PractRes Clin Gastroenterol 2007; 21: 205-14.
2. Suebaum S, Michetti P. Helicobacter pylori infection. N EnglJ Med 2002; 347: 1175-86.
3. Current European Concepts in the management of Helicobacter pylori infection. The Maastricht Consensus Report. European Helicobacter pylori Study Group. Gut 1997; 41: 8-13.
4. Guillen D, McColl KEL. Gastroduodenal disease,Helicobacter pylori, and genetic polymorphisms. ClinicalGastroenterol Hepatol 2005; 3: 1180-86.
5. Argent RH, Kidd M, Owen RJ, Thomas RJ, Limb MC,Atherton JC. Determinants and consequences of different levels of Cag A phosforilation for clinical isolates of Helicobacter pylori. Gastroenterology 2004; 127: 514-23.
6. Howden CW, Hunt RH. Guidelines for the managementof Helicobacter pylori. Ad Hoc Committee on practice parametersof the American College of Gastroenterology. Am JGastroenterol 1998; 93: 2330-8.
7. Bytzer P, O ́Morain C. Treatment of Helicobacter pyloriHelicobacter 2005; 10(Suppl 1): 40-46.
8. Chey WD, Wong BCY. American College of Gastroenterology Guideline on the Management of Helicobacter pylori Infection. Am J Gastroenterol 2007; 102: 1808-25.
9. Malfertheiner P, Megraud F, ÓMorain C, Bazzoli F, El-OmarE, Graham D, et al. Current concepts in the management of Helicobacter pylori infection- The Maastricht III consensus report. Gut 2007; 56: 772-81.
10. Vakil N, Megraud F. Eradication therapy for Helicobacter pylori. Gastroenterology 2007; 133: 985-100.
11. Graham DY, Shiotani A. New concepts of resistence in thetreatment of Helicobacter pylori infections. Nature Clin PractGastroenterol Hepatol 2008; 5: 321-31.
12. Megraud F. Helicobacter pylori antibiotic resistance: prevalence,importance and advances in testing. Gut 2004; 53:137-84
13. Gutierrez O, Otero W. Resistencia de Helicobacter pylori alMetronidazol en Colombia. Rev Col Gastroenterol 1998;12: 31-5.
14. Clinical and laboratory Standards Institute. Methods for antimicrobial dilution and disk susceptibility testing for infrequently isolated or fast idious bacteria 2006(5):M2-M7.Pen. USA.
15. Cotton PB, Williams CB. Practical Gastrointestinal endoscopy:The fundamentals (5th edition), Oxford: BlackwellPublishing Ltd. 2003.
16. El-Zimaity HM, Graham DY. Evaluation of gastric mucosalbiopsy site and number for identification of Helicobacterpylori or intestinal metaplasia: role of the Sydney system.Hum Pathol 1999; 30: 72-7.
17. Guamer J, Herrera-Goepfert R, Mohar A, Smith C, Schofield, A, Halperin D, et al. Diagnostic yield of gastric biopsy specimenswhen screening for preneoplastic lesions. Hum Pathol 2003; 34: 28-35.
18. Genta RM, Graham DY. Diagnosis and treatment ofHelicobacter pylori. En Graham DY, Genta RM, Dixon MF.Gastritis. Lippincott Williams &Wilkins Phil 1999. p. 189-201.
19. Quiroga AJ, Cittelly DM, Maria Bravo MM. Frecuencia delos genotipos babA2, oipA y cagE de Helicobacter pylori enpacientes colombianos con enfermedades gastroduodenales.Biomedica 2005; 25: 325-34.
20. Ansorg R, Von Recklinghausen G, Pomarius R, Schmid EN.Evaluation of Techniques for Isolation, subcultivation, and Preservation of Helicobacter pylori. J Clin Microbiol 1991;29(1): 51-53.
21. Cittelly DM, Huertas MG, Martinez JD, Oliveros R, PossoH, Bravo MM, et al. Helicobacter pylori genotypes in nonatrophic gastritis are different of the found in peptic ulcer,premalignant lesions and gastric cancer in Colombia. RevMed Chile 2002; 130: 143-51.
22. Martinez A, Gonzalez C, Kawauchi F, Montoya F.Helicobacter pylori: analisis de cagA y genotipificacion devacA en Chile. Deteccion de una cepa s2/m1. Rev MedChile 2001; 129: 1147-1153.
23. Osato MS. Antimicrobial Susceptibility Testing for Helicobacter pylori: Sensitivity Test Results and Their ClinicalRelevance. Curr Pharm Des 2000; 6: 1545-1555.
24. Glupczynski Y, Labbe M, Hansen W, Krocaert F,Yourassowsky E. Evaluation of the E Test for Quantitative Antimicrobial Susceptibility Testing of Helicobacter pylori. JClinical Microbiol 1991; 29: 2072-2075.
25. Osato MS, Reddy R, Reddy SG, Penland RL, Graham DY.Comparison of the Etest and the NCCLS-approved agardilution method to detect metronidazole and clarithromycinresistant Helicobacter pylori. Int J Antimicr 2001; 17: 39-44.
26. Blaser MJ, Atherton JC. Helicobacter pylori persistent: biologyand disease. J Clin Invest 2004; 113: 321-33.
27. Houben MHM, van de Beck D, Hensen EF, De Craen AJM,Waws EAJ, Tytgat GNJ. A systematic review of Helicobactereradication therapy-the impact of antimicrobial resistance on eradication rates. Aliment Pharmacol Ther 1999; 13:1047-55.
28. Datta S, Chattopadhyay S, Patra R, Ramamurthy R de T,Hembram J, Chowdhury S, et al. Most Helicobacter pyloristrains of Kolkata in India are resistant to metronidazole but susceptible to other drugs commonly used for eradicationand ulcer therapy. Aliment Pharmacol Ther 2005; 22: 51-7.
29. Torres J, Camorlinga-Ponce M, Perez-Perez G, Madrazo Dela Garza A, Dahesa M, Gonzalez-Valencia G, et al. Increasingmultidrug resistance in Helicobacter pylori strains isolated from children and adults in Mexico. J Clin Microbiol 2001;39: 2677-80.
30. Henao SC, Otero W, Angel LA, Martinez JD. Resistenciaprimaria a Metronidazol en aislamientos de Helicobacterpylori en pacientes adultos de Bogota. Rev Col Gastroenterol 2009; 24: 10-15.
31. Glupzynski Y, Megraud F, Lopez Brea M. European multicentersurvey of in vitro antimicrobial resistance in Helicobacter pylori. Eur J Clin Microbial Infect Dis 2000;11: 820-3.
32. Osato MS, Reddy R, Reddy SG, Penland RL, Malaty HM,Graham DY. Pattern of primary resistance of Helicobacterpylori to metronidazole or claritrhomycin in the UnitedStates. Arch Intern med 2001; 161: 1217-20.
33. Megraud F. Helicobacter pylori resistance to antibiotics:prevalence, mechanism, detection. What's new? Can JGastroenterol 2003; 17(Suppl. B): 49B-52B.
34. Henao SC, Quiroga A, Martinez JD, Otero W. Resistenciaprimaria a la claritromicina en aislamientos de Helicobacterpylori. Rev Col Gastroenterol 2009; 24: 110-114.
35. Alvarez A, Moncayo JI, Santaccruz JJ, Santacoloma M,Corredor LF, Reinosa E. Antimicrobial susceptibility andmutations invlved in clarithromycin resistance in Helicobacterpylori isolates from patients in the western central region ofColombia. Antimicr Ag Chemother 2009; 53: 40222-4.
36. Vakil N. H. pylori treatment: new wine in old bottles? Am JGastroenterol 2009; 104: 26-30.
37. Duck WM, Sobel J, Prukler JM, et al. Antimicrobial resistance incidence and risk factors among Helicobacter pyloriinfectedpersons. United states Emerg Infect Dis 2004;10:1088-94.
38. Jefri NS, Hornung CA, Howden CW. Meta-analysis:sequential therapy appears superior to standard therapy for Helicobacter pylori infection in naive patients. Ann InternMed 2008; 148: 923-31.
39. Vaira D, Zulo A, Vakil N, Gatta L, Ricci C, Perna F, et al.Sequential therapy versus standard triple drug therapy for Helicobacter pylori eradication. Ann Intern Med 2007; 146:556-63.
40. Gisbert JP, Fernandez M, Molina J, Perez A, Prieto B,Matos JM, et al. First line triple therapy with levofloxacin for Helicobacter pylori eradication. Alimen Pharmacol Ther 2007; 26: 495-500.
41. Nista EC, Candelli M, Zocco MA, Cremonini F, Ojeti M,Finizio R, et al. Levofl oxacin-based triple therapy in firstline treatment for Helicobacter pylori eradication. Am JGastroenterol 2006; 101: 1985-90.
42. Schrauwen RWM, Jannssen MJR, de Boer WA. Seven-dayPPI triple therapy with levofl oxacin is very effective for Helicobacter pylori infection. J Med 2009; 67: 96-101.
43. Cheng HC, Chang WL, Chen WY, Yang HB, WU JJ, Sheu, BS. Levofloxacin-containing triple therapy to eradicate thepersistent H. pylori aft er a failed conventional triple therapy.Helicobacter 2007; 12: 359-63.
44. Perna F, Zullo A, Ricci C, Hassan C, Morini S, Vaira D.Levofl oxacin -based triple therapy for Helicobacter pylorire-treatment: role of bacterial resistance. Dig Liv Dis 2007;39: 1001-5.
45. Gisbert JP, Bermejo F, Castro M, Aisa A, Fernandez M,Tomas A, et al. Second Line therapy with levofl oxacin after H. pylori treatment failure: a Spanish multicenter study of 300 patients. Am J gastroenterol 2008; 103: 71-6.
46. Di Caro S, Franceschi F, Mariani A, Thompson F, Raimondo, D, Masci E, Testoni A, et al. Second line levofl oxacin basedtriple schemes for Helicobacter pylori eradication. Dig LivDis 2009;41:480-85
47. Gisbert JP, Castro M, Bermejo F, Perez A, Ducons J,Fernandez M, Bory F, et al. Third line rescue therapy withlevofl oxacin after two H. pylori treatment failures. Am JGastroenterol 2006; 101: 243-7.
48. Lwal-Lume L, Ogutu EO, Amayo EO, et al. Drug susceptibility pattern of Helicobacter pylori in patients with dyspepsiain Kenyatta National Hospital Nairobi. East Afr Med J 2005;82: 603-8.
49. Nahar S, Mukhopadhay AK, Khan R, et al. Antimicrobial susceptibility of Helicobacter pylori strains isolated in Bangladesh. J Clin Microbiol 2004; 42: 4856-58.
50. Godoy AP, Ribeiro ML, Benvengo YH, Vitiello L, MirandaM de C, et al. Analysis of antimicrobial susceptibility andvirulence factors in Helicobacter pylori clinical isolates. BMC Gastroenterol 2003; 11(3): 20.
51. Debets-Ossenkopp YJ, Reyes G, Mulder J, Aan de Stegge BM,Peters JT, Savelkoul PH, Tanca J, Pena AS, Vandenbroucke-Grauls CM. Characteristics of clinical Helicobacter pyloristrains from Ecuador. J Antimicrob Chemother 2003; 51:141-145.
52. Lopez-Brea M, Martinez MJ, Domingo D, Sanchez I,Alarcon T. Metronidazole resistance and virulence factors in Helicobacter pylori as markers for treatment failure in a paediatricpopulation. FEMS Immunol Med Microbiol 1999;24: 183-8.
53. Zschausch HC, Han SR, Meyer HG, Maeurer MJ. No association between Helicobacter pylori genotypes and antibioticresistance phenotypes within families. Helicobacter 2002;7: 364-6.
54. Taneike I, Nami A, O'Connor A, Fitzgerald N, Purphy P,Oasim A, et al. The analysis of drug resistance and virulent factor genotype of Irish Helicobacter pylori strains: is thereany relationship between to metronidazole and cagA status?Aliment Pharmacol Ther 2009; Jul 9 (Epub ahead of print).